S

Syndax Pharmaceuticals
D

SNDX

16.370
USD
0.38
(2.38%)
مغلق
حجم التداول
229,139
الربح لكل سهم
-3
العائد الربحي
-
P/E
-4
حجم السوق
1,397,305,140
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    1.200
    (0.60%)
    202.140 USD
    AZN
    AZN
    -0.350
    (-0.47%)
    74.220 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    NVO
    NVO
    4.355
    (5.20%)
    88.090 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    المزيد
الأخبار
المقالات

العنوان: Syndax Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.